ArticleMethods in molecular biology (Clifton, N.J.)2026
Enrichment of Phosphorylated and Glycosylated MHC Peptides for Mass Spectrometry-Based Neoantigen Analysis.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycosylation and phosphorylation are two of the most important forms of post-translational modification. Their dysregulation is related to tumorigenesis with phosphorylating enzymes, known as kinases, having been shown to active cancerous signaling pathways, and aberrant glycosylation has been detected in various types of cancers. For immunotherapy using neoantigens, both glycosylated and phosphorylated peptides presented exclusively on tumor cells by the major histocompatibility complex (MHC) are promising candidates due to their specificity to elicit cytotoxic T-cell responses. Unlike other MHC-presented peptides, glycosylated and phosphorylated MHC peptides cannot be predicted by bioinformatic tools, and their identification relies on specific enrichment from the whole immunopeptidome and sensitive detection with mass spectrometry. Herein, we describe a workflow that sequentially enriches glycosylated and phosphorylated MHC peptides from the immunopeptidome with hydrophilic interaction chromatography and titanium dioxide nanoparticles, followed by analysis of enriched peptides by liquid chromatography tandem mass spectrometry and identification of modified MHC peptides by database searching.
Indexed as
Identifiers
41085622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.